Advanced search
Publication Cover
Infection and Drug Resistance Volume 15, 2022 - Issue
Submit an article Journal homepage
186
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Population-Based Pharmacokinetics and Dose Optimization of Imipenem in Vietnamese Critically-Ill Patients

Thanh D Dinh1 Department of Clinical Pharmacy, Hanoi University of Pharmacy, Hanoi, Vietnam;2 Phu Tho General Hospital, Việt Trì, Phu Tho Province, Vietnam
,
Hung N Nguyen1 Department of Clinical Pharmacy, Hanoi University of Pharmacy, Hanoi, Vietnam
,
Ba Hai Le1 Department of Clinical Pharmacy, Hanoi University of Pharmacy, Hanoi, VietnamORCID Iconhttps://orcid.org/0000-0003-3301-1374
ORCID Icon,
Thuy TT Nguyen1 Department of Clinical Pharmacy, Hanoi University of Pharmacy, Hanoi, Vietnam
&
Huong TL Nguyen1 Department of Clinical Pharmacy, Hanoi University of Pharmacy, Hanoi, VietnamCorrespondence[email protected]
Pages 4575-4583 | Published online: 17 Aug 2022

References

  • Yoshizawa K, Ikawa K, Ikeda K, Kumon H, Ohge H, Morikawa N. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data. Int J Antimicrob Agents. 2012;40(5):427–433. doi:10.1016/j.ijantimicag.2012.06.011
  • Chen W, Zhang D, Lian W, et al. Imipenem population pharmacokinetics: therapeutic drug monitoring data collected in critically Ill patients with or without extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2020;64(6):6. doi:10.1128/AAC.00385-20
  • Couffignal C, Pajot O, Laouenan C, et al. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens. Br J Clin Pharmacol. 2014;78(5):1022–1034. doi:10.1111/bcp.12435
  • Nguyen TM, Ngo TH, Truong AQ, et al. Population pharmacokinetics and dose optimization of ceftazidime and imipenem in patients with acute exacerbations of chronic obstructive pulmonary disease. Pharmaceutics. 2021;13:4. doi:10.3390/pharmaceutics13040456
  • Legrand T, Chhun S, Rey E, et al. Phạm. Developing a method for the quantitative determination of three carbapenem antibiotics in plasma by HPLC. Pharm Res Drug Inform. 2004;1:12–16.
  • Lavielle M. mlxR: simulation of longitudinal data. Available from: http://simulx.webpopix.org. Accessed January 20, 2021.
  • Dreetz M, Hamacher J, Eller J, et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob Agents Chemother. 1996;40(1):105–109. doi:10.1128/AAC.40.1.105
  • Suchankova H, Lips M, Urbanek K, Neely MN, Strojil J. Is continuous infusion of imipenem always the best choice? Int J Antimicrob Agents. 2017;49(3):348–354. doi:10.1016/j.ijantimicag.2016.12.005
  • Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother. 2007;51(9):3304–3310. doi:10.1128/AAC.01318-06
  • Wicha SG, Märtson AG, Nielsen EI, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109(4):928–941. doi:10.1002/cpt.2202
  • Jaruratanasirikul S, Wongpoowarak W, Jullangkoon M, Samaeng M. Population pharmacokinetics and dosing simulations of imipenem in serious bacteraemia in immunocompromised patients with febrile neutropenia. J Pharmacol Sci. 2015;127(2):164–169. doi:10.1016/j.jphs.2014.12.003
  • Drusano GL, Standiford HC, Bustamante C, et al. Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother. 1984;26(5):715–721. doi:10.1128/AAC.26.5.715
  • Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d’Anesthésie et Réanimation-SFAR). Crit Care. 2019;23(1):104. doi:10.1186/s13054-019-2378-9
  • Prescott WA Jr, Gentile AE, Nagel JL, Pettit RS. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis. Pharm Ther. 2011;36(11):723–763.
  • Sornsuvit C, Wientong P, Uitrakul S, Okonogi S, Katip W. Influence of concentration and temperature on stability of imipenem focused on solutions for extended infusion. Dose-Response. 2021;19(4):155932582110593. doi:10.1177/15593258211059325
  • Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44(10):1009–1034. PMID: 16176116. doi:10.2165/00003088-200544100-00002
  • World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. PMID: 24141714. doi:10.1001/jama.2013.281053

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.